{"Clinical Trial ID": "NCT00209092", "Intervention": ["INTERVENTION 1:", "Bras A: Sequential therapy", "Docetaxel should be administered intravenously at 100 mg/m^2 Day1 every 3 weeks for 4 cycles, followed by capecitabine 1000 mg/m^2 twice daily orally D1-14 every 3 weeks for 4 cycles (total of 8 cycles) (total of 24 weeks).", "INTERVENTION 2:", "Bras B: Simultaneous therapy", "Docetaxel should be administered intravenously at 50 mg/m^2 Day 1 in combination with capecitabine 1000 mg/m^2 twice daily by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks)."], "Eligibility": ["Incorporation criteria:", "A histologically or cytologically confirmed breast carcinoma.", "\u2022 Early breast cancer (stage 1, 2, 3).", "There is no evidence of disease outside the breast or chest wall, with the exception of ipsilateral axillary lymph nodes.", "- 18 years or older.", "The final eligibility for a clinical trial is determined by the health care professionals conducting the trial.", "- Exclusion criteria:", "\u2022 Prior chemotherapy, hormone therapy, biological therapy or radiotherapy for breast cancer.", "A major surgical procedure within 28 days of entry into the study.", "Evidence of central nervous system (CNS) metastases.", "The final eligibility for a clinical trial is determined by the health care professionals conducting the trial."], "Results": ["Performance measures:", "Number of participants with a complete pathological response rate to preoperative A-arm therapy (Docetaxel for 4 cycles followed by Capecitabine for 4 cycles) or B-arm therapy (Docetaxel + Capecitabine for 8 cycles) in patients with early breast cancer.", "There is no invasive breast cancer in the breast.", "Overall clinical response=Complete response (complete removal of CCR from any measurable malignant disease)+partial response (reduction of PR by at least 30%)", "No decrease or < 25% increase in the sum of products of the longest perpendicular diameters of all measurable lesions.", "A 20% or more increase in a single injury, OR a recurrence of any missing injury, OR a net aggravation of any evaluable disease OR the occurrence of any new injury/site.", "Time limit: 1 year", "Results 1:", "Title of the arm/group: Sequential therapy", "Docetaxel should be administered intravenously at 100mg/m^2 Day1 every 3 weeks for 4 cycles, followed by capecitabine 1000 mg/m^2 twice daily orally D1-14 every 3 weeks for 4 cycles (total of 8 cycles) (total of 24 weeks).", "Total number of participants analysed: 25", "Type of measurement: Number", "Unit of Measure: Pathological Participants Complete Response - Overall Population: 2", "Overall clinical response: 15", "Stable disease: 3", "Progressive diseases: 7", "Results 2:", "Title of arm/group: Bras B: Simultaneous therapy", "Docetaxel should be administered intravenously at 50mg/m^2 Day 1 in combination with capecitabine 1000 mg/m^2 twice daily orally Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).", "Total number of participants analysed: 26", "Type of measurement: Number", "Unit of Measure: Pathological Participants Complete Response - Overall Population: 3", "Overall clinical response: 23", "Stable disease: 1", "Progressive diseases: 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/25 (24.0%)", "Neutropenia *3/25 (12.0%)", "Anemia *0.25 (0.00 %)", "Febrile Neutropenia *0.25 (0.00 %)", "Thoracic pain *0.25 (0.00 %)", "Diarrhoea *1/25 (4.0%)", "\u2022 Fatigue *1/25 (4.0%)", "Liver tests *0.25 (0.00 %)", "Neuropathy *0.25 (0.00 %)", "- Syncope *0.25 (0.00 %)", "Hand and foot syndrome *1/25 (4.0%)", "Adverse Events 2:", "Total: 11/26 (42.31 per cent)", "Neutropenia *3/26 (11.54 %)", "Anemia *1/26 (3.85 per cent)", "1/26 (3.85 per cent)", "*1/26 (3.85 per cent)", "Diarrhoea *1/26 (3.85 per cent)", "Fatigue *0/26 (0.00 %)", "Liver tests *1/26 (3.85%)", "Neuropathy *1/26 (3.85%)", "- Syncope *1/26 (3.85 %)", "Hand and foot syndrome *1/26 (3.85 per cent)"]}